This week’s decision to relocate the European Medicines Agency to Amsterdam has been greeted as the least damaging outcome for the European Union's medicines regulator, which must leave Lon
The location of the European Medicines Agency after Brexit is to be decided today, as representatives of member states vote in a complex secret ballot that could end with a coin toss.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
